期刊
JOURNAL OF CLINICAL LIPIDOLOGY
卷 4, 期 5, 页码 346-349出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacl.2010.08.013
关键词
Familial hypercholesterolemia; LDL; Apheresis; Statins; Patient selection
资金
- ISIS
- Genzyme Corporation
Options for treatment of severe heterozygous and homozygous familial hypercholesterolemia prior to the statin era were limited by significant side effects and morbidity. The advent of both the statins and technology for the selective removal of LDL via apheresis have revolutionized management but challenges remain. (C) 2010 National Lipid Association. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据